Evidence map›Paper›PMID 31768631›Full record

SynthesisRheumatology international2021

Aortic involvement in relapsing polychondritis: case-based review.

Mustafa Erdogan, Sinem Nihal Esatoglu, Gulen Hatemi, Vedat Hamuryudan

Abstract readCase ReportsSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. [Relapsing polychondritis].Zeitschrift fur Rheumatologie · 2023
    Article
  6. Review
  7. Mimickers of Large Vessel Giant Cell Arteritis.Journal of clinical medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mustafa ErdoganDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University - Cerrahpasa, Cerrahpasa, 34998, Istanbul, Turkey.
Sinem Nihal EsatogluDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University - Cerrahpasa, Cerrahpasa, 34998, Istanbul, Turkey.
Gulen HatemiDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University - Cerrahpasa, Cerrahpasa, 34998, Istanbul, Turkey.
Vedat HamuryudanDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University - Cerrahpasa, Cerrahpasa, 34998, Istanbul, Turkey. vedathamuryudan@yahoo.com.ORCID http://orcid.org/0000-0001-6625-1652
Istanbul University-Cerrahpaşa · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsing polychondritis is a systemic inflammatory disease that mainly affects ears, nose, eyes, joints, and large airway. Relapsing polychondritis may also affect cardiac valves and large vessels with the aorta being most frequently involved. We conducted a systematic literature review to delineate the clinical characteristics, treatment, and outcome of relapsing polychondritis patients with aortic involvement including thoracic and abdominal aorta, aortic valve, and coronary arteries. 113 patients reported in 85 manuscripts were retrieved through the systematic literature search and references of the selected manuscripts. With the addition of a patient from our center, a total of 114 patients were included in the analyses. Aortic vessel involvement was the predominant type of involvement that was identified in 93 (82%) patients, while aortic valve involvement was identified in 41 patients (36%). The median age at aortic involvement was 37 years [IQR: 30-53] with a delay of 5 years [IQR: 1-8] between first relapsing polychondritis symptom and aortic involvement. Nineteen percent of the patients were asymptomatic at the time of aortic involvement diagnosis. The initial treatment was immunosuppressives in 41 patients (56%) and surgery in 28 patients (38%). The mortality ratio was 27% in a 24 month follow-up [IQR: 7.5-54 months]. Aortic dissection or rupture was the most frequent causes of mortality. Concomitant coronary artery involvement suggested a worse outcome. Aortic involvement in relapsing polychondritis is a mortal complication despite medical and surgical treatments. It may be asymptomatic in 19% of the patients which warrants the importance of screening.

Indexed as

AdultAortic AneurysmAortic ValveAortitisComputed Tomography AngiographyCyclophosphamideFemaleFluorodeoxyglucose F18HumansInfliximabMethylprednisolonePolychondritis, RelapsingPositron Emission Tomography Computed TomographyPrednisoloneTomography, X-Ray ComputedTreatment OutcomeCyclophosphamideFluorodeoxyglucose F18InfliximabMethylprednisolonePrednisoloneAortic aneurysmAortic valveAortitisPolychondritisVasculitis

Identifiers

PMID31768631
OpenAlexW2990703303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.